Author: Ken Dropiewski

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Coronary/Structural Heart by Comments are Disabled

BOSTON and SEATTLE, Dec. 18, 2024 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, today announced that its wholly owned preclinical subsidiary for disease modelling and drug discovery, Novoheart, has entered into a transformative partnership with Curi Bio Inc., a leader in preclinical screening technologies. This strategic collaboration integrates Novoheart’s industry-leading human Heart-in-a-Jar technology with Curi Bio’s advanced Pulse™ analytics platform, delivering an innovative solution for accelerated, high-content, human-based cardiac drug development.

Continue Reading →

CardioFocus Announces First Patients Treated with OptiShot™ Pulsed Field Ablation System

Rhythm by 0 comments

December 17, 2024 03:09 PM Eastern Standard Time MARLBOROUGH, Mass.–(BUSINESS WIRE)–CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the first series of patients treated with the investigational OptiShot™ Pulsed Field Ablation (PFA) System for the treatment of paroxysmal atrial fibrillation as part […]

Continue Reading →

Scott Burger Appointed as CEO of AngioInsight, Inc.

Financial by 0 comments

MINNETONKA, Minn.–(BUSINESS WIRE)–AngioInsight, Inc., an innovator in medical imaging technologies, is pleased to announce the appointment of Scott Burger as its Chief Executive Officer (CEO). Scott brings over two decades of extensive leadership experience in the healthcare and medical technology sectors, positioning him perfectly to lead AngioInsight into its next […]

Continue Reading →

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Coronary/Structural Heart by 0 comments

December 17, 2024 08:00 AM Eastern Standard Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages of the […]

Continue Reading →

Neuvotion Expands Partnership with Intelligent Product Solutions and Commercializes NeuStim™ Technology for Stroke and Spinal Cord Injury

Neuro by Comments are Disabled

STAMFORD, Conn., Dec. 17, 2024 /PRNewswire/ — Neuvotion, Inc. is an early-stage medical device company developing AI-driven neuromodulation technologies and products for use in the neurorehabilitation, brain-computer interface (BCI), and physical therapy markets. Today Neuvotion has…

Continue Reading →

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Financial by Comments are Disabled

Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update.

Continue Reading →

Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director

Financial by 0 comments

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or “Adagio”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer (“CEO”) and Chairperson of the Board of Directors of the Company, effective December 13, […]

Continue Reading →

First-In-Human Study Demonstrates the Potential of the Reprieve System in Patients with Acute Decompensated Heart Failure

Coronary/Structural Heart by 0 comments

December 16, 2024 08:00 AM Eastern Standard Time MILFORD, Mass. & FRANKFURT, Germany–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the first-in-human results of the Reprieve System at the CSI Focus D-HF (Device therapies in heart failure) conference in Frankfurt, […]

Continue Reading →

HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

Coronary/Structural Heart by 0 comments

First cable-free, ambulatory ECG that captures the heart’s electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate […]

Continue Reading →
1 … 188 189 190 191 192 … 1,339